Technical Analysis for PRTG - Portage Biotech Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.26 | 5.11% | 0.01 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 5.11% | |
| NR7 | Range Contraction | 5.11% | |
| NR7-2 | Range Contraction | 5.11% | |
| Wide Bands | Range Expansion | 5.11% | |
| Oversold Stochastic | Weakness | 5.11% | |
| Shooting Star Candlestick | Bearish | -14.20% | |
| Stochastic Buy Signal | Bullish | -14.20% | |
| Volume Surge | Other | -14.20% | |
| Calm After Storm | Range Contraction | -14.20% | |
| NR7 | Range Contraction | -14.20% |
| Alert | Time |
|---|---|
| Possible NR7 | 25 minutes ago |
| 60 Minute Opening Range Breakout | about 3 hours ago |
| Rose Above Previous Day's High | about 3 hours ago |
| 3x Volume Pace | about 3 hours ago |
| Up 10% | about 3 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/29/2024
Portage Biotech Inc. Description
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Immunology Solid Tumors Immune System Antibodies Antiviral Drug Interferon Acute Kidney Injury Biotechnology Products Natural Killer T Cell
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.4 |
| 52 Week Low | 0.1999 |
| Average Volume | 108,975 |
| 200-Day Moving Average | 1.61 |
| 50-Day Moving Average | 0.51 |
| 20-Day Moving Average | 0.43 |
| 10-Day Moving Average | 0.33 |
| Average True Range | 0.10 |
| RSI (14) | 31.03 |
| ADX | 17.26 |
| +DI | 17.64 |
| -DI | 22.82 |
| Chandelier Exit (Long, 3 ATRs) | 0.33 |
| Chandelier Exit (Short, 3 ATRs) | 0.51 |
| Upper Bollinger Bands | 0.68 |
| Lower Bollinger Band | 0.19 |
| Percent B (%b) | 0.11 |
| BandWidth | 113.27 |
| MACD Line | -0.08 |
| MACD Signal Line | -0.07 |
| MACD Histogram | -0.0181 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.32 | ||||
| Resistance 3 (R3) | 0.33 | 0.31 | 0.31 | ||
| Resistance 2 (R2) | 0.31 | 0.29 | 0.30 | 0.30 | |
| Resistance 1 (R1) | 0.28 | 0.28 | 0.27 | 0.27 | 0.30 |
| Pivot Point | 0.26 | 0.26 | 0.25 | 0.25 | 0.26 |
| Support 1 (S1) | 0.22 | 0.24 | 0.21 | 0.22 | 0.19 |
| Support 2 (S2) | 0.20 | 0.22 | 0.20 | 0.18 | |
| Support 3 (S3) | 0.17 | 0.20 | 0.18 | ||
| Support 4 (S4) | 0.16 |
